Antibody responses to melanoma/melanocyte autoantigens in melanoma patients

Journal of Investigative Dermatology

Volumn 111, Issue 4, 1998, Pages 662-667

  Huang, Sharon K S ^a   Okamoto, Tetsuro ^a   Morton, Donald L ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Autoimmunity; gp100; TRP 2; Vaccine

Indexed keywords

AUTOANTIGEN; CANCER VACCINE; IMMUNOGLOBULIN G; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE;

ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; DNA RECOMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOTHERAPY; MELANOGENESIS; MELANOMA; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 0031704548     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00354.x     Document Type: Article

References (43)

1. Adema GJ, de Boer AJ, Vogel AM, Loenen WAM, Figdor CG: Molecular characterization of the melenocyte lineage-specific antigen gp 100. J Biol Chem 269:20126-20133, 1994
2. Alarcon-Segovia D, Ruiz-Arguelles A, Llorente L: Broken dogma: penetration of autoantibodies into living cells. Immunol Today 17:163-164, 1996
3. Baharav E, Merimsky O, Altomonte M, et al: Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Melanoma Res 5:337-343, 1995
4. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994
5. Berd D, Mastrangelo MJ, Lattinie E, Sato T, Maguire HCJr: Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol Immunother 42:263-267, 1996
6. Bouchard B, del Marinol V, Jackson IJ, Cherif D, Dubertret L: Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells. Eur J Biochem 219:127-134, 1994
7. Brichard V, Van Pel A, Wolfel T, et al: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489-495, 1993
8. Bystryn JC, Oralz R, Roses D, Harris M, Henn M, Lew R: Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157-1164, 1992
9. Cui J, Harning R, Henn M, Bystryn J-C: Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 98:162-165, 1992
10. Doi F, Chi DDJ, Charuworn BB, Conrad AJ, Russell J, Morton DL, Hoon DSB: Detection of β-human chorionic gonadotropin mRNA as a marker for. cutaneous malignant melanoma. Int J Cancer 65:454-459, 1996
11. Fishman P, Merimski O, Baharav E, Shoenfeld Y: Autoantibodies to tyrosinase. The bridge betwwen melanoma and vitiligo. Cancer 79:1461-1464, 1997
12. Fleiss J: Statistical Methods of Rates and Proportions. New York: John Wiley, 1981 pp. 112-123
13. Hoon DSB, Wang Y, Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13:2109-2116, 1995a
14. Hoon DSB, Yuzuki D, Hayashida M, Morton DL: Melanoma patients immunized with melanoma cell vaccine induce antibody response to recombinant MAGE-1 antigen. J Immunol 154:730-737, 1995b
15. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1-4, 1994
16. Jackson IJ: A cDNA encoding tyrosinase-related protein maps to the brown locus in mouse. Proc Natl Acad Sci USA 85:4392-4396, 1988
17. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981
18. Kawakami Y, Rosenberg SA: Immunobiology of human melanoma antigens MART-I and gp100 and their use for immuno-gene therapy. Int Rev Immunol 14:173-192, 1997
19. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP: Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 109:495-500, 1997
20. Kobayashi T, Urabe K, Winder A, et al: Tyrosinase-related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. Embo J 13:5818-5825, 1994
21. Kwon BS: Pigmentation genes: the tyrosinase gene family and thr pmel 17 gene. Family J Invest Dermatol 100:134S-140S, 1993
22. Kwon BS, Chintamaneni C, Kozak CA, et al: A melanocyte-specific gene. Pmel 17. maps near the sliver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. Proc Natl Acad Sci USA 88:9228-9232, 1991
23. Livingston PO, Wong GYC, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
24. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT: New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11-24, 1996
25. del Marmol V, Beermann F: Tyrosinase and related proteins in mammalian pigmentation. Febs Lett 381:165-168, 1996
26. Mattes MJ, Thomson TM, Old LJ, Lloyd KO: A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 32:717-721, 1983
27. Merinsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigelman R, Cohen-Aloro D, Fishman P: Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother 42:297-302, 1996
28. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S: Kinetics of the immune response and regression of metastatic lesions following Development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 54:415-421, 1994
29. Morton DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
30. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN: Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93:14809-14814, 1996
31. Naughton GK, Eisinger M, Bystryn J-C Antibodies to normal human melanocytes in vitiligo. J Exp Med 158:246-251, 1983
32. Okamoto T, Kaneda Y, Yuzuki D, Huang SKS, Chi DDJ, Hoon DSB: Induction of antibody response to human tumor antigens by gene therapy using a fusiogenic viral liposome vaccine. Gene Ther 4:969-976, 1997
33. Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou B-K, Silvers WK, Mintz B: Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA 92:10152-10156, 1995
34. Sarantou T, Chi DDJ, Garrison DA, Conrad AJ, Schmid P, Morton DL, Hoon DSB: Melanoma-associated antigen as messenger RNA detection markers for melanoma. Cancer Res 57:1371-1376, 1997
35. Song Y-H, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N: The role of tyrosinase in autoimmune vitiligo. Lancet 344:1049-1052, 1994
36. Spagnoli GC, Schaefer C, Willimann TE, et al: Peptide-specific CTI in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-I Melan-A, gp100 and tyrosinase genes: a study in an unselective group of Hl A-A2.1-positive patients. Int J Cancer 64:309-315, 1995
37. Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN: A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 2:1837-1842, 1996
38. Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJ: A second tyrosinase-related protein. TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. Embo J 11:519-526, 1992
39. Tuttosi S, Bretscher PA: Antigen-specific CD8+ T cells switch the immune response induced by antigen from an IgG to a cell-mediated mode. J Immunol 148:397-403, 1992
40. Vijayasaradhi S, Bouchard B, Houghton AN: The melanoma antigen gp75 is the human homologoue of the mouse β (brown) locus gene product. J Exp Med 171:1375-1380, 1990
41. Wang R-F, Robbins RF, Kawakami Y, Kang X-Q, Rosenberg SA: Identification of a gene eneoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799-804, 1995
42. Wang R-F, Appella E, Kawakami Y, Kang X, Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207-2216, 1996
43. Zhai Y, Yang JC, Kawakami Y, et al: Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MARTI or gp100 for cancer therapy. J Immunol 156:700-710, 1996